Drug and Therapeutics Bulletin 1998;36:62-64; doi:10.1136/dtb.1998.36862
Copyright © 1998 by the BMJ Publishing Group Ltd.

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation

Meloxicam-a safer NSAID?

Relevant BNF section: 10.1.1.

Non-steroidal anti-inflammatory drugs (NSAIDs) block the enzyme cyclo-oxygenase (COX), thereby reducing the synthesis of prostaglandins from arachidonic acid. This blockade is believed to be responsible for both the therapeutic (anti-inflammatory) and many of the unwanted effects of NSAIDs.¹ It is now recognised that COX exists in two functionally distinct isoforms: COX-1 is active continuously and catalyses the synthesis of prostaglandins with physiologically protective effects (e.g. on the gastric mucosa), while COX-2 is induced during inflammation.^2,3 Meloxicam (Mobic - Boehringer Ingelheim), which has been available in the UK for 2 years, is marketed as an NSAID with "COX-2 selectivity" in vitro, and so one which "in theory...should have a better GI side-effect profile". Is meloxicam an advance on traditional NSAIDs?

This article has been cited by other articles:

				A. Dickman and J. Ellershaw For Discussion NSAIDs: gastroprotection or selective COX-2 inhibitor? Palliative Medicine, June 1, 2004; 18(4): 275 - 286. [Abstract] [PDF]